CAS Number3522-50-7
SynonymsCitric acid iron; MFCD00013098; Iron citrate; Citric acid, iron salt; Iron(3+) citrate; EINECS 219-045-4; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron (3+) salt (1:1); Iron(iii) citrate; Citric acid, iron (3+) salt (1:1); Ferric citrate; EFRRIC CITRATE; Einecs 222-536-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1); Citric acid iron(III) salt; Iron(III)citrate
Molecular FormulaC6H5FeO7
Molecular Weight244.94
Purity98.00%
Density1.762g/cm3
Boiling Point309.6ºC at 760 mmHg
Appearancesolid
EINECS222-536-6
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 3522-50-7 |
| Catalog No. | 2A-9029904 |
| Chinese Name | 柠檬酸铁 |
| Synonyms | Citric acid iron; MFCD00013098; Iron citrate; Citric acid, iron salt; Iron(3+) citrate; EINECS 219-045-4; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron (3+) salt (1:1); Iron(iii) citrate; Citric acid, iron (3+) salt (1:1); Ferric citrate; EFRRIC CITRATE; Einecs 222-536-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1); Citric acid iron(III) salt; Iron(III)citrate |
| Molecular Formula | C6H5FeO7 |
| Molecular Weight | 244.94 |
| Purity | 98.00 |
| Density | 1.762g/cm3 |
| Boiling Point | 309.6ºC at 760 mmHg |
| Appearance | solid |
| Storage Condition | Store at room temperature, away from light, in a v |
| Application | Ferric citrate is an oral active iron supplement that is an effective phosphate binder. Ferric citrate can be used in the study of iron deficiency anemia and chronic kidney disease (CKD). |
| EINECS | 222-536-6 |
| HTC | 2918150000 |
| PubChem ID | 24894843 |
| MDL Number | MFCD00013098 |
| SMILES | OC12CC(=O)O[Fe](OC(=O)C1)OC2=O |
| InChI | 1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3 |
| InChI Key | NPFOYSMITVOQOS-UHFFFAOYSA-K |
| NACRES Code | NA.75 |
| UNSPSC | 12352205 |
| Hazard Symbols | transportation |
| MSDS | msds/29904_1_3522_50_7.pdf |
| Bioactivity | Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research. Related Catalog Research Areas >> Metabolic Disease In Vitro Ferric citrate (Iron(III) citrate; 1 mM; 24 hours) significantly induces CM cell death[1]. Ferric citrate (Iron(III) citrate; 0.1 mM, 1 mM, 2 mM; 24 hours) increases ROS generation in cardiomyocyte (CM) cells in a dose-dependent manner[1]. Cell Viability Assay[1] Cell Line: Cardiomyocyte (CM) cells Concentration: 1 mM Incubation Time: 24 hours Result: Significantly induced CM cell death. In Vivo Here we compared the effects of Ferric citrate (25 μg/g) administration versus a mineral sufficient control diet using the Col4a3 knockout mouse model of progressive CKD and age-matched wild-type mice. Ferric citrate is given to knockout mice for four weeks beginning at six weeks of age when they had overt chronic kidney disease (CKD), or for six weeks beginning at four weeks of age when they had early CKD. Ferric citrate rescues iron deficiency and anemia in knockout mice regardless of the timing of treatment initiation, and circulating levels and bone expression of FGF23 are reduced. Ferric citrate also improves cardiac function and significantly improves survival[3]. Ferric citrate is an efficacious and safe phosphate binder that increases iron stores and reduces intravenous iron and erythropoietin-stimulating agent use while maintaining hemoglobin. Ferric citrate can increase transferrin saturation, serum ferritin, and hemoglobin[2]. References [1]. Yuichi Baba, et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H659-H668. [2]. Julia B Lewis, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015 Feb;26(2):493-503. [3]. Connor Francis, et al. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. Kidney Int. 2019 Dec;96(6):1346-1358. Chemical & Physical Properties Density 1.762g/cm3 Boiling Point 309.6ºC at 760 mmHg Molecular Formula C6H5FeO7 Molecular Weight 244.945 Flash Point 155.2ºC Exact Mass 244.938477 PSA 140.62000 Vapour Pressure 5.73E-05mmHg at 25°C Index of Refraction 1.575 Storage condition Store at RT. Stability Stable. Incompatible with strong oxidizing agents. |
| Use of | Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research. Properties Articles73 Name Iron(III) citrate Synonym More Synonyms Ferric Citrate Biological Activity Description Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research. Related Catalog Research Areas >> Metabolic Disease In Vivo Here we compared the effects of Ferric citrate (25 μg/g) administration versus a mineral sufficient control diet using the Col4a3 knockout mouse model of progressive CKD and age-matched wild-type mice. Ferric citrate is given to knockout mice for four weeks beginning at six weeks of age when they had overt chronic kidney disease (CKD), or for six weeks beginning at four weeks of age when they had early CKD. Ferric citrate rescues iron deficiency and anemia in knockout mice regardless of the timing of treatment initiation, and circulating levels and bone expression of FGF23 are reduced. Ferric citrate also improves cardiac function and significantly improves survival[3]. Ferric citrate is an efficacious and safe phosphate binder that increases iron stores and reduces intravenous iron and erythropoietin-stimulating agent use while maintaining hemoglobin. Ferric citrate can increase transferrin saturation, serum ferritin, and hemoglobin[2]. References [1]. Yuichi Baba, et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H659-H668. [2]. Julia B Lewis, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015 Feb;26(2):493-503. Chemical & Physical Properties Molecular Formula C6H5FeO7 Exact Mass 244.938477 PSA 140.62000 Index of Refraction 1.575 Storage condition Store at RT. Stability Stable. Incompatible with strong oxidizing agents. |
| Tax Rebate | 13.0% |
| Supervision | 4. Export license A. Customs clearance form for inbound goods B. Customs clearance form for outbound goods x. Export license (processing trade) y. Export license (small-scale border trade) |
| Inspection | R. Imported food hygiene supervision and inspection S. Export food hygiene supervision and inspection N. Export commodity inspection |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| 2,6-Dimethylpyridin-4-amine | 3512-80-9 | 2A-9029890 |
| 2-Methylene-1,3-propanediol | 3513-81-3 | 2A-9029891 |
| 3-Cyanopropanal | 3515-93-3 | 2A-9029892 |
| 4-Methoxyphenyl methyl sulfone | 3517-90-6 | 2A-9029895 |
| 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide | 3520-43-2 | 2A-9029900 |
| 5-Benzyl hydantoin | 3530-82-3 | 2A-9029911 |
| 3,3-Diphenylacrylonitrile | 3531-24-6 | 2A-9029913 |
| 3,4-Dimethoxybenzoyl chloride | 3535-37-3 | 2A-9029914 |
| 5-tert-Butyl-2-methoxyaniline | 3535-88-4 | 2A-9029915 |
| Butyl 4-bromobutyrate | 3540-75-8 | 2A-9029918 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS